7,091,051 Shares in Certara, Inc. $CERT Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. purchased a new position in shares of Certara, Inc. (NASDAQ:CERT) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 7,091,051 shares of the company’s stock, valued at approximately $46,446,000. Jefferies Financial Group Inc. owned 4.65% of Certara as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CERT. Granite Investment Partners LLC acquired a new position in Certara in the first quarter valued at $2,130,000. Dimensional Fund Advisors LP boosted its stake in shares of Certara by 2.1% during the first quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock worth $48,806,000 after buying an additional 175,024 shares during the period. UBS Group AG grew its holdings in shares of Certara by 50.7% during the fourth quarter. UBS Group AG now owns 2,489,603 shares of the company’s stock worth $21,933,000 after buying an additional 837,648 shares during the last quarter. Quantinno Capital Management LP grew its holdings in shares of Certara by 412.5% during the first quarter. Quantinno Capital Management LP now owns 988,990 shares of the company’s stock worth $5,637,000 after buying an additional 796,007 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Certara by 1,097.6% in the 1st quarter. Renaissance Technologies LLC now owns 354,500 shares of the company’s stock valued at $2,021,000 after acquiring an additional 324,900 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Price Performance

Shares of CERT opened at $8.41 on Friday. Certara, Inc. has a twelve month low of $4.45 and a twelve month high of $13.88. The stock’s 50 day moving average is $7.31 and its two-hundred day moving average is $6.46. The firm has a market capitalization of $1.28 billion, a PE ratio of -18.69 and a beta of 1.44. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.30.

Certara (NASDAQ:CERT) last issued its earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $93.27 million for the quarter, compared to analysts’ expectations of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The business’s quarterly revenue was down 10.8% on a year-over-year basis. During the same period last year, the company posted $0.07 earnings per share. Research analysts anticipate that Certara, Inc. will post 0.22 earnings per share for the current year.

Analysts Set New Price Targets

CERT has been the subject of several analyst reports. Barclays upped their price objective on Certara from $6.50 to $7.50 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. Morgan Stanley cut their price target on Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Craig Hallum decreased their price target on Certara from $10.00 to $8.00 and set a “hold” rating for the company in a report on Tuesday, May 12th. Robert W. Baird lowered their price objective on shares of Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 12th. Finally, BMO Capital Markets dropped their price objective on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Certara has a consensus rating of “Hold” and an average target price of $8.28.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.